University of California San Francisco
Helen Diller Family Comprehensive Cancer Center
Miguel Hernandez Pampaloni, MD, PhD

Miguel Hernandez Pampaloni, MD, PhD

Associate Professor, Nuclear Medicine Chief, Dept of Radiology, UCSF

Cancer Center Program Memberships

Experimental Therapeutics

Research Summary

Miguel Hernandez Pampaloni, MD, PhD, is an Associate Professor of Radiology and Medicine and the Chief of Nuclear Medicine in the Department of Radiology and Biomedical Imaging at the University of California, San Francisco. Dr. Pampaloni is responsible for all clinical, administrative, and research coordination, performance and supervision of diagnostic and therapeutic studies within the section. Dr. Pampaloni earned his PhD in Radiological Sciences from the Universidad Complutense School of Medicine in Madrid, Spain, and he obtained his MD from the Universidad Complutense School of Medicine. Dr. Pampaloni completed a residency in Nuclear Medicine at the San Carlos Hospital in Madrid, Spain, and he completed a residency in Nuclear Medicine at the University of Pennsylvania School of Medicine. Dr. Pampaloni was a postdoctoral fellow in Cardiovascular Nuclear Medicine at the David Geffen School of Medicine at UCLA, and he joined the UCSF Nuclear Medicine Section as an Assistant Professor in 2009. Dr. Pampaloni is an active member of the Hellen Diller Cancer Center, including being a member of the Cutaneuous Oncology Site Committee, the Development Therapeutics Group and the Hematology Group.

Dr. Pampaloni has two main research interests: applications of molecular imaging into the cardiovascular field and oncology. He is interested in assessing the preclinical pathophysiological changes in the inflammatory process at the base of the coronary artery disease and the mechanism controlling the vascular proliferation in metastatic solid tumors by the development of noninvasive imaging probes. As part of vascular biology characteristics, he is interested in applying new developed radioligands to target specific processes in the angiogenesis of cancer. In addition, he is developing new imaging strategies to assess the immune activation in the setting of therapy response.

Dr. Pampaloni has written over 80 peer reviewed articles, 6 book chapters, 100 abstracts.

Education

Universidad Complutense, Madrid, MD 1990
Universidad Complutense, Madrid, PhD 1998


Professional Experience

  • 1993-1996
    Nuclear Medicine Residency, San Carlos Hospital, Madrid
  • 1998-2002
    Postdoctoral Fellowship, Department of Molecular & Medical Pharmacology, University of California Los Angeles
  • 2002-2003
    Clinical Research Fellow, Imperial College, London
  • 2004-2006
    Research Assistant Professor, Children’s Hospital of Philadelphia, PA
  • 2006-2008
    Resident in Nuclear Medicine, Hospital of the University of Pennsylvania
  • 2008-2009
    Clinical Instructor, Dept of Radiology, Hospital of the University of Pennsylvania
  • 2009-present
    Assistant Professor, Dept of Radiology, UCSF
  • 2010-present
    Chief, Nuclear Medicine, Dept of Radiology, UCSF

Honors & Awards

  • 2002
    Society of Nuclear Medicine Meeting, Cardiovascular Young Investigator Award
  • 1999
    Spanish Society of Cardiology Annual Meeting, Best Communication Award

Selected Publications

  1. Hernandez Pampaloni M, Facchetti L, Nardo L. Pitfalls in [¹⁸F]FDG PET imaging in gynecological malignancies. Q J Nucl Med Mol Imaging. 2016 Jun;60(2):124-38. Epub 2016 Mar 3. Review. PubMed PMID: 26937887.
  2. Daud AI, Loo K, Pauli ML, Sanchez-Rodriguez R, Sandoval PM, Taravati K, Tsai K, Nosrati A, Nardo L, Alvarado MD, Algazi AP, Pampaloni MH, Lobach IV, Hwang J, Pierce RH, Gratz IK, Krummel MF, Rosenblum MD. Tumor immune profiling predicts response to anti-PD-1 therapy in human melanoma. J Clin Invest. 2016 Sep 1;126(9):3447-52. doi: 10.1172/JCI87324. Epub 2016 Aug 15. PubMed PMID: 27525433; PubMed Central PMCID: PMC5004965.
  3. TA. Hope, M Hernandez Pampaloni, R R. Flavell, E K. Nakakura, E K. Bergsland. Somatostatin receptor PET/MRI for the evaluation of neuroendocrine tumors. Q J Nucl Med Mol Imaging 2016.
  4. Tsai KK, Pampaloni MH, Hope C, Algazi AP, Ljung BM, Pincus L, Daud AI J Increased FDG avidity in lymphoid tissue associated with response to combined immune checkpoint blockade. Immunother Cancer. 2016 Sep 20;4:58. doi: 10.1186/s40425-016-0162-9. eCollection 2016.PMID:27660712
  5. Barajas RF, Krohn KA, Link JM, Hawkins RA, Clarke JL, Pampaloni MH, Cha S. Glioma FMISO PET/MR Imaging Concurrent with Antiangiogenic Therapy: Molecular Imaging as a Clinical Tool in the Burgeoning Era of Personalized Medicine. Biomedicines. 2016 Oct 31;4(4). pii: E24. doi: 10.3390/biomedicines4040024.
  6. Villablanca JG, Ji L, Shapira-Lewinson A, Marachelian A, Shimada H, Hawkins RA, Pampaloni M, Lai H, Goodarzian F, Sposto R, Park JR, Matthay KK.Predictors of response, progression-free survival, and overall survival using NANT Response Criteria (v1.0) in relapsed and refractory high-risk neuroblastoma. Pediatr Blood Cancer. 2018 Jan 19. doi: 10.1002/pbc.26940.
  7. E Stieglitz, T Dinh, A Phelps, Pampaloni MH, A Olshen E Robbins. ABVD without Radiation for Newly Diagnosed Pediatric Patients with Hodgkin Lymphoma: A Single Center Retrospective Analysis of 28 Consecutive Patients. Journal of Pediatric, Hematology and Oncology, 2018 Feb 9. doi: 10.1097/MPH.